Eli Lilly and Boehringer Ingelheim will undercut Sanofi by 15% with Basaglar, a biosimilar version of the insulin blockbuster Lantus launched today in the US.

Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with ...

Earlier in the week, Novo Nordisk followed Eli Lilly Co.'s plans to slash U.S. prices by up to 75% and 70%, respectively. Sanofi said it will cut the price of Lantus by 78% and short-acting Apidra ...

Eli Lilly will likely draw investor focus on Monday as the company said its investigational once-weekly insulin efsitora alfa ...

Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials ...

Lilly also will reduce the price of its nonbranded, fast-acting insulin to $25 a vial, effective May 1. On April 1, Lilly also will launch a biosimilar to Sanofi's Lantus that will be a less ...

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday ...

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw ...

Health policy experts say Eli Lilly's competitors—Sanofi, which makes Apidra and Lantus, and Novo Nordisk, which makes NovoLog and Levemir—are now facing increasing pressure to respond.

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

Further, Lilly said in April it plans to launch a biosimilar to Lantus, which will cost $92 for a five pack of pens. About the Author. Jaimy Lee.